Williams Chris, Simera Iveta, Bryant Andrew
Cochrane Gynaecological Cancer Review Group, Royal United Hospital, Combe Park, Bath, UK, BA1 3NG.
Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD001034. doi: 10.1002/14651858.CD001034.pub2.
Tamoxifen is an important drug for treating breast cancer. Ovarian cancer cells are known to possess receptors for hormones and may thus also respond to tamoxifen.
Tamoxifen is used to treat breast cancer in women whose tumours have oestrogen receptors. Since ovarian cancers also commonly have oestrogen receptors, it has been suggested that tamoxifen may be of some benefit. The objective of this review was to assess the effects of tamoxifen in women with relapsed ovarian cancer.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 1, 2009. Cochrane Gynaecological Cancer Group Trials Register, MEDLINE from 2002 to April 2009, EMBASE from 2002 to April 2009. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of review articles and contacted experts in the field, as well as drugs companies.
Randomised and non-randomised studies of tamoxifen in women with ovarian cancer who have not responded to conventional chemotherapy. Only trials involving 10 or more patients were included.
Two review authors independently assessed whether potentially relevant studies met the inclusion criteria. No trials were found and therefore no data were analysed.
The search strategy identified 1392 unique references of which 1360 were excluded on the basis of title and abstract. The remaining 32 articles were retrieved in full, but none satisfied the inclusion criteria. Only observational data from single arm studies of women treated with tamoxifen were reported.
AUTHORS' CONCLUSIONS: We are unable to make any evidence-based recommendations as we found no comparative studies assessing the effectiveness of tamoxifen in women with recurrent ovarian cancer. There is limited evidence on anti-tumour activity from phase 2 studies, but these contain no data on the effect of tamoxifen on symptom control, QOL or the prolongation of life.
他莫昔芬是治疗乳腺癌的一种重要药物。已知卵巢癌细胞拥有激素受体,因此也可能对他莫昔芬产生反应。
他莫昔芬用于治疗肿瘤具有雌激素受体的女性乳腺癌患者。由于卵巢癌通常也有雌激素受体,有人提出他莫昔芬可能会有一定益处。本综述的目的是评估他莫昔芬对复发性卵巢癌女性患者的疗效。
我们检索了《Cochrane系统评价数据库》(CENTRAL)2009年第1期、Cochrane妇科癌症小组试验注册库、2002年至2009年4月的MEDLINE以及2002年至2009年4月的EMBASE。我们还检索了临床试验注册库、科学会议摘要、综述文章的参考文献列表,并联系了该领域的专家以及制药公司。
关于他莫昔芬用于对传统化疗无反应的卵巢癌女性患者的随机和非随机研究。仅纳入涉及10名或更多患者的试验。
两名综述作者独立评估潜在相关研究是否符合纳入标准。未找到试验,因此未进行数据分析。
检索策略共识别出1392篇独特参考文献,其中1360篇基于标题和摘要被排除。其余32篇文章全文获取,但均不符合纳入标准。仅报告了他莫昔芬治疗女性患者的单臂研究的观察性数据。
由于未找到评估他莫昔芬对复发性卵巢癌女性患者疗效的比较研究,我们无法给出任何基于证据的建议。来自2期研究的抗肿瘤活性证据有限,且这些研究未包含他莫昔芬对症状控制、生活质量或延长生命影响的数据。